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Most cell types acquire cholesterol by endocytosis of circulat-
ing low density lipoprotein, but little is known about the mech-
anisms of intra-endosomal cholesterol transport and about the
primary cause of its aberrant accumulation in the cholesterol
storage disorder Niemann-Pick type C (NPC). Here we report
that lysobisphosphatidic acid (LBPA), an unconventional phos-
pholipid that is only detected in late endosomes, regulates endo-
somal cholesterol levels under the control of Alix/AlP1, which is
an LBPA-interacting protein involved in sorting into multive-
sicular endosomes. We find that Alix down-expression
decreases both LBPA levels and the lumenal vesicle content of
late endosomes. Cellular cholesterol levels are also decreased,
presumably because the storage capacity of endosomes is
affected and thus cholesterol clearance accelerated. Both lume-
nal membranes and cholesterol can be restored in Alix knock-
down cells by exogenously added LBPA. Conversely, we also
find that LBPA becomes limiting upon pathological cholesterol
accumulation in NPC cells, because the addition of exogenous
LBPA, but not of LBPA isoforms or analogues, partially reverts
the NPC phenotype. We conclude that LBPA controls the cho-
lesterol capacity of endosomes.
Endocytosed proteins and lipids destined for degradation,
such as down-regulated signaling receptors and LDL,4 are
sequentially transported to early and late endosomes, and even-
tually to lysosomes. A hallmark of endosomes along this degra-
dation pathway is their multivesicular appearance due to the
accumulation of intralumenal vesicles. These incorporate
down-regulated receptors (1, 2) and cholesterol (3, 4) and also
contain large amounts of LBPA (or bis(monoacylglycero)phos-
phate), which is only detected in late endosomes (5).
In addition to their presence in intralumenal vesicles, LBPA
and cholesterol have been linked functionally. Both are affected
by sterol carrier protein-2 expression (6). Moreover, LBPA
plays a role in cholesterol transport (7). Some relationship
between cholesterol and LBPA has also been revealed in the
cholesterol storage disorder Niemann-Pick type C caused by
mutations in NPC1 or NPC2, whose precise functions are not
known (8–10). In tissues from NPC patients, cholesterol accu-
mulation is paralleled by the accumulation of LBPA and other
lipids, in particular sphingolipids (8, 10–12). We previously
found that LBPA functions may be controlled by Alix, which
binds LBPA-containing bilayers (13). Interestingly, Alix is
involved in sorting into multivesicular endosomes (14, 15).
Moreover, both Alix and LBPA also play a role in intralumenal
vesicle fission from and fusion with the endosome limiting
membrane (13, 16, 17).
Here we report that Alix down-expression decreases both
the lumenal membrane content of late endosomes and their
LBPA level, whereas the cellular cholesterol level is reduced,
presumably because the endosomal storage capacity is affected.
Indeed, the addition of exogenous LBPA to Alix knockdown
cells restores both the intralumenal membrane content of late
endosomes and the cholesterol level. Conversely, we find that
LBPAbecomes limiting upon pathological cholesterol accumu-
lation in NPC cells, because the addition of exogenous LBPA,
but not of LBPA isoforms or analogues, reverts the NPC phe-
notype. We conclude that LBPA controls the cholesterol stor-
age capacity of endosomes.
EXPERIMENTAL PROCEDURES
Cells and Reagents—Baby hamster kidney cells (BHK-21),
HeLa cells, and NPC skin fibroblasts were maintained as
described previously (7), as was the production and purification
of vesicular stomatitis virus (VSV Indiana serotype) (18). We
previously described the synthesis of enantiopure 2,2- and
3,3- dioleoyl-LBPA (13, 19), which can now be obtained from
Echelon Biosciences Inc. (Salt Lake City, UT), and of (R,R)- and
(S,S)-bisether analogues of LBPA (20). Other lipids were pur-
chased from Avanti Polar Lipids, Inc. We also previously
described the 6C4 monoclonal antibody against LBPA (5). The
monoclonal antibodies against a cytoplasmic (P5D4) (21) or
* Thisworkwas supported by the Swiss National Science Foundation and the
Telethon (to J. G.) and theAustralianNationalHealth andMedical Research
Council (to R. G. P.). The costs of publication of this article were defrayed in
part by thepayment of page charges. This articlemust therefore behereby
marked “advertisement” in accordancewith 18U.S.C. Section 1734 solely to
indicate this fact.
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. S1–S4.
1 Both authors contributed equally to this work.
2 Present address: Anatomy and Cell Biology Dept., 3640 University St., Mon-
treal, Quebec H3A 2B2, Canada.
3 To whom correspondence should be addressed. Fax: 41-22-379-6470;
E-mail: jean.gruenberg@biochem.unige.ch.
4 The abbreviations used are: LDL, low density lipoprotein; NPC, Niemann-
Pick type C; LBPA, lysobisphosphatidic acid; BHK, baby hamster kidney;
siRNA, short interfering RNA; ELISA, enzyme-linked immunosorbent assay;
HRP, horseradish peroxidase; DOPC, dioleolylphosphatidylcholine; DOPE,
dioleolylphosphatidylethanolamine; VSV, vesicular stomatitis virus.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 283, NO. 41, pp. 27871–27880, October 10, 2008
© 2008 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
OCTOBER 10, 2008•VOLUME 283•NUMBER 41 JOURNAL OF BIOLOGICAL CHEMISTRY 27871
 at UQ Library on October 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at UQ Library on October 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
LBPA and Endosomal Cholesterol
27872 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 41•OCTOBER 10, 2008
 at UQ Library on October 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
exoplasmic (17.2.21.4) (22) VSV G-protein epitope were
described, as well as the polyclonal antibody against G-protein
(22). Anti-apolipoprotein A2 was purchased from Biodesign
International (Saco, ME). Reagents were obtained from the fol-
lowing sources: anti-mouse Dynabeads fromDynal (Oslo, Nor-
way); n-octylpolyoxyethylene from Bachem (Bubendorf, Swit-
zerland); silencer siRNA labeling kit Cy3 from Ambion, Inc.
(Huntingdon, UK); fluorescently labeled secondary antibod-
ies from Jackson ImmunoResearch; R18 from Molecular
Probes (Eugene, OR); TRIzol from Invitrogen; and U18666A
(3--[2-(diethylamino)ethoxy]androst-5-en-17-one) from
Biomol (Plymouth Meeting, PA).
Analysis of the Genomic Sequence of ALIX siRNA Target in
Hamster Cells—RNA from BHK or HeLa cells was extracted
with TRIzol according to the manufacturer’s instructions.
Then 0.5 g of total RNA was used for reverse transcription
with SuperscriptTMRT (Invitrogen) using random hexamer.
The transcribed DNA was subjected to TaqMan reverse tran-
scription-PCR using two primers (forward primer, 5 GGT
GCA GCT GAA GAA GAC CT 3; reverse primer, 5 CAG
GTT CTGCTC TGCAAT 3). For TaqMan real time PCR, we
used the ICycler.IQTM (Bio-Rad). Specific PCR bands were
excised and purified. TheDNAwas cloned into a TOPOvector,
according to the manufacturer’s instructions (Invitrogen).
TOP10 bacteria were then transformed and grown; DNA was
isolated and then sequenced for analysis by Fasteris SA
(Geneva, Switzerland).
Microscopy—The analysis of cholesterol distribution after
filipin staining by fluorescence microscopy was described, as
was the analysis of LBPA (7) or other antigens (17) by immuno-
fluorescencemicroscopy. To visualize the content of late endo-
somes by electron microscopy, HRP was endocytosed for 15
min at 37 °C and then chased for 30min inmarker-freemedium
(18). Cells were then fixed, and HRP was revealed cytochemi-
callywith 3,3-diaminobenzidine as substrate and processed for
plastic embedding (23). Micrographs were taken at random
across the monolayer, and then sets of micrographs were ana-
lyzed in a blind fashion by an independent observer.
Proteoliposomes Containing VSV-G Protein and LBPA—The
major LBPA (90%) isoform in BHK is 2,2-dioleoyl-LBPA (5,
19, 24). This isoform was synthesized (19) and used to prepare
liposomes by reverse phase evaporation with a phospholipid
composition (DOPC/DOPE/LBPA, 60:20:20 mol) similar to
that of late endosomes, where LBPA normally resides (5).
Because living cells do not take up liposomes efficiently, the
G-glycoprotein of vesicular stomatitis virus (VSV-G) was
incorporated into the liposomes, to increase cell surface bind-
ing and targeting to the endocytic pathway. Thus, liposome
delivery was independent of the lipid composition.
To prepare the G-protein, purified VSV (800 g) was sedi-
mented for 2 h at 4 °C in a TLA100.3 centrifuge at 90,000 rpm.
The supernatant was carefully discarded. The white pellet was
resuspended in 0.6 ml of 0.1% n-octylpolyoxyethylene in HBS
(20mMHepes, pH 7.4, 150mMNaCl), by 6–8 passages through
a yellow tip until the solution became clear. Then the tubes
were gently mixed at room temperature on a rotary wheel (4
rpm) (in 0.6 ml) for 1 h to facilitate detergent extraction of the
G-protein. The mixture was then centrifuged at 4 °C for 1 h at
50,000 rpm (TLA 100.3) to separate soluble and nonsoluble
materials. The supernatants were collected, dialyzed six times
against 250ml of HBS at 4 °C to remove the detergent, and used
to prepare proteoliposomes or aliquoted, flash-frozen in liquid
N2, and stored at90 °C.
Lipsomes were prepared by reverse phase evaporation (13),
after dissolving lipids in CHCl3, and mixed at the following
molar ratios: DOPC/DOPE (60:40 mol); DOPC/DOPE/choles-
terol (60:20:20 mol); DOPC/DOPE/LBPA (60:20:20 mol); and
DOPC/GM3 (70:30mol). Lipids (total10mg)were then dried
under reduced pressure and dissolved in 1.5 ml of water-satu-
rated diethyl ether and 0.5 ml of HBS (aqueous phase) contain-
ing 50 g of G-glycoprotein (equivalent to 200 g of VSV
with G 26% of VSV mass). In some experiments, 10 M R18,
a lipophylic fluorescent dye, was added. The mixture was vor-
texed and then sonicated continuously for 3 min on ice with a
probe-type sonicator (Sonifier 250, Branson) set on power 3.
Diethyl ether was then evaporated slowly at 600 mbar for
30–60 min under nitrogen flux on a rotatory evaporator, until
lipids become oily. Then 1 ml of HBS (containing the fluores-
cent dye, if necessary) was added, and the solution was evapo-
rated twice for 30 min on a rotatory evaporator at a 500-mbar
pressure and then at 300 mbar until no smell of ether was
detected, indicating that full reversion had occurred. When
needed, we quantified R18 (excitation 560 nm; emission 585
nm) incorporation into liposomes with a SPECTRAmax GEM-
INI XS spectrophotometer and SOFTmax Pro (Molecular
Devices), as described previously (13).When living cells (grown
in 6-cm diameter Petri dishes) were treated with liposomes, the
growth medium was replaced by 3 ml of Glascow minimum
essential medium containing 10 mM Hepes, pH 7.4, and 0.2%
bovine serum albumin, which was then complemented with
100 l of the desired liposome preparation (0.66 mg of total
lipid). The sameoperationwas then repeated every 2 h, until the
end of the incubation (after 8 h).
FIGURE 1. Alix and LBPA. A, BHK cells were treated with siRNAs against Alix (siRNA Alix) or mock-treated (control, ctrl) for 72 h. Alix siRNAs were identical to
those used in human cells (13), because their target region is identical in hamster (see supplemental Fig S1A). Cells were then stained with filipin to reveal
cholesterol and with antibodies against LBPA, and analyzed by double-channel fluorescence microscopy. LBPA and cholesterol are decreased after Alix
knockdown (but both exhibit their characteristic punctate pattern at longer exposure times, not shown). Stars indicate the position of cell nuclei. B, BHK cells
were treated with Alix siRNAs and homogenized. Total cell extracts were prepared, and both LBPA and cholesterol were quantified. Values are expressed as
arbitrary units (AU). C,mock- or Alix siRNA treated BHK cells were fractionated by floatation in a sucrose gradient (50). After centrifugation, heavymembranes
(HM), early endosomes (EE), and late endosome (LE) fractions were collected, and the LBPA content of each fraction was quantified by ELISA. Themean of four
different experiments is shown. The inset shows an analysis by Western blotting using antibodies against Alix or annexin 2 (Anx2); annexin 2, which is also
involved in endosomemembrane dynamics (2), was not affected.D and E, late endosome content of BHK cells treatedwith Alix siRNAs (E) or mock-treated (D)
as in Awas labeled with HRP pulsed for 15 min at 37 °C and chased for 30 min. Cells were then fixed and processed for HRP cytochemistry and embedded in
plastic. Bar, 1 m.
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To quantify the incorporation of VSV-G and to determine its
trans-bilayer orientation, proteoliposomes (prepared by
reverse phase evaporation as above) were immunopurified
using Dynabeads coated with antibodies against an exoplasmic
(17.2.21.4) or cytoplasmic (P5D4) epitope of theG-protein (18).
Similarly, we analyzed the antigenicity of LBPA incorporated
into liposomes by incubating 50 l of the liposome prepara-
tion with 15 l of anti-LBPA antibody in 135 l of HBS for
3 h at 4 °C. Then the antibody bound to liposomes was sep-
arated from free antibody by floatation in a step sucrose
gradient (17). In each case, samples were analyzed by SDS-
gel electrophoresis under nonreducing conditions, followed
by Western blotting using a polyclonal antibody against
VSV-G to detect the G-protein or anti-mouse antibodies to
detect the anti-LBPA antibody.
To determine the pH-dependent fusion properties of lipo-
somes, we used the following: 1) as acceptor, DOPC/DOPE/
LBPA (60:20:20) liposomes containing the G-protein; 2) as
donor containing R18, liposomes were passed through a PD-10
SephadexG-25 column (AmershamBiosciences) to remove the
nonencapsulated dyeR18. Then 100l of donorR18-liposomes
weremixed at 4 °Cwith 50l of acceptor liposomes and 50l of
HBS (neutral conditions) or 50l of Tris maleic acid, pH 5.6, in
150 mM NaCl (acidic conditions). The temperature was raised
to 22 °C, and the emitted fluorescence (excitation, 560; emis-
sion 585) wasmeasured over 90min with a Photon Technology
International fluorimeter (710 Photomultiplier system detec-
tion and LPS 220 lamp).
Other Methods—SDS-gel electrophoresis (25) and the quan-
tification of LBPA by ELISA (5) and cholesterol (26) were
described. Down-regulation of Alix expression in BHK cells
with siRNAswas as described inHeLa cells (13) except that cells
were split (1/20) the day before the experiment and then again
(biochemistry, 1/4; immunofluorescence, 1/20) 48 h after
siRNA addition. Gene expression was quantified from HeLa
cells submitted or not to Alix siRNAs. For each condition, RNA
was purified from two independent 10-cm dishes using the
RNeasy minikit (Qiagen). Reverse transcription-PCR was per-
formed using the Superscript II kit (Invitrogen) and oligo(dT)
primer (Promega). The following amplificationwasmade on an
i-cycler (Bio-Rad) with the Quantitect SYBR Green PCR kit
(Qiagen). The Quantitect Primers (Qiagen) for the following
genes were used: SREBPF2, DHC7R, ACTB, HMGCR, SDHA,
LDLR, and PDCD6IP (Alix).
RESULTS ANDDISCUSSION
Formation of Intralumenal Membranes—To investigate
LBPA functions in cholesterol storage and transport, we
silenced Alix expression in BHK cells (supplemental Fig. S1A),
because we had characterized LBPA in these cells. We had
determined the atomic composition of the BHKmajor (90%)
LBPA isoform as 2,2-dioleoyl-LBPA (supplemental Fig. S1B).
We had also characterized the subcellular distribution and late
endosomal content of LBPA (15 mol % of total phospholipids)
in BHKcells (5, 19, 24) (see Fig. 1C). UponAlix knockdown (Fig.
1C, inset), the LBPA staining intensity was decreased (Fig. 1A),
as observed by others (27) and us (13) in human cells, as was the
LBPA content of late endosomal fractions (Fig. 1C).
Because LBPA is a major phospholipid of late endosome
lumenal membranes (5) and because it is decreased by Alix
knockdown, we wondered whether the ultrastructure of late
endosomes was affected in Alix knockdown cells. To this end,
the lumen of late endosomes was labeled with endocytosed
HRP pulsed for 15 min and then chased for 30 min at 37 °C.
Cells were then processed for HRP cytochemistry and electron
microscopy, and micrographs taken at random were analyzed
in a blind fashion. In control, mock-treated cells, HRP-labeled
late endosomes contained numerous lumenal inclusions and
vesicles, exhibiting the characteristic multivesicular ultrastruc-
ture of this compartment in BHK cells (18) (Fig. 1D). By con-
trast, in Alix knockdown cells, HRP-positive endosomes
appeared like empty vacuoles with a few internal vesicles (Fig.
1E), consistent with observations that LBPA levels are then
reduced (Fig. 1, A–C). These data agree well with our previous
findings thatAlix knockdown inHeLa cells reduces LBPA levels
and the number of multilamellar late endosomes that are typi-
cal for these cells (13).
Alix and Cholesterol—We then investigated whether choles-
terol was affected in Alix knockdown cells, because LBPA and
cholesterol are linked functionally (6–8, 12) and because LBPA
and cholesterol are both present in intralumenal endosomal
vesicles, although perhaps in different subpopulations (3, 28).
Upon filipin staining of mock-treated control cells, cholesterol
was mostly present at the plasma membrane by light micros-
copy but was also faintly detected in intracellular structures,
presumably trans-Golgi network and endosomes (Fig. 1A), as
expected (8, 29). Strikingly, the overall cholesterol staining
intensity decreased in Alix knockdown cells concomitantly
with decreased LBPA staining (Fig. 1A), and biochemical quan-
tification showed that, much like LBPA, the total cellular cho-
lesterol was then reduced by30% (Fig. 1B).
We could rule out the possibility that decreased cholesterol
levels were because of an inhibition of LDL endocytosis,
because Alix knockdown does not affect endocytosis nor trans-
port along the endocytic pathway toward late endosomes and
lysosomes or lysosomal degradation (13, 16, 17, 27, 30). Simi-
larly, Alix knockdowndid not seem to affect de novo cholesterol
synthesis, because the expression of genes involved in choles-
terol synthesis and accumulation was unchanged (supplemen-
tal Fig. S2). Alternatively, Alix down-expression, with a con-
comitant depletion of LBPA (Fig. 1, A–C) and loss of lumenal
membranes (Fig. 1E), may affect the capacity of multivesicular
endosomes to store or retain cholesterol. Thismay affect NPC1
functions in cholesterol transport, because NPC1 is normally
present both in intralumenal vesicles and on the limitingmem-
brane of multivesicular endosomes (31). In turn, this may alter
cellular cholesterol levels, because endosomal and cellular cho-
lesterol levels are interdependent (29). Upon release from
endosomes, perhaps via NPC1 and NPC2, as well as ABCA1
(32) or other members of this protein superfamily (33), choles-
terol is rapidly transported to the cell surface (34–36) by vesic-
ular and nonvesicular routes (29). Efflux into the medium and
capture by serum carriers, including high density lipoprotein
(37) can then occur. We could not measure cholesterol in the
medium, because of the necessary presence of fetal calf serum
in these RNA interference experiments. However, we hypoth-
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esized that in the absence of Alix
and LBPA, cholesterol may be inef-
ficiently retained in endosomes, and
thus cellular clearance may be
accelerated.
Cholesterol Accumulation—To
test whether Alix and LBPA may
play a role in cholesterol clearance
from endosomes, we made use of
U18666A, a drug that mimics the
NPC phenotype by causing acute
accumulation of LDL-derived cho-
lesterol in the late endosomes of
cells with a nonpathological genetic
background (7, 38) (Fig. 2, A and B).
Interestingly, LBPA and cholesterol
levels changed concomitantly in
U18666A-treated cells. Like choles-
terol, LBPA increased in U18666A-
treated cells incubated in the pres-
ence of serum (Fig. 2B). Conversely,
cholesterol did not accumulate in
U18666A-treated cells incubated in
serum-free medium (Fig. 2B), as
expected (38). LBPA similarly
showed no increase in U18666A-
treated cells incubated in serum-
free medium (Fig. 2B), demonstrat-
ing that LBPA accumulation in
U18666A-treated cells did not
result from some effects of the drug
on lipid neo-synthesis, and further
confirm the notion that LBPA and
cholesterol are intimately linked.
Cholesterol accumulated within
intracellular vesicles in U18666A-
treated cells, as predicted (38) (Fig.
2A), which correspond to LBPA-
positive late endosomes (Ref. 7) and
data not shown). InAlix knockdown
cells, accumulation still occurred,
albeit with slower kinetics (supple-
mental Fig. S3), and eventually
reached levels comparable with
controls (Fig. 2A, t 0; after 16 h of
U18666A treatment). We then
monitored cholesterol clearance
from these pre-loaded endosomes
after drug washout. The intensity of
the cholesterol staining rapidly
(over 6 h) decreased in Alix knock-
down cells, when compared with
controls (Fig. 2A). This may suggest
that U18666A was less efficiently
retained within the endosomes of
knockdown cells upon washout.
Alternatively, it is possible that cho-
lesterol was more efficiently cleared
FIGURE2.Alix and cholesterol.A,mock-treatedorAlix siRNA-treatedBHK cellswere treatedwithU18666A for
16 h. The drug was removed, and cells were further incubated in drug-free medium for the indicated times.
Cells were labeled with filipin and analyzed by fluorescence microscopy. Stars indicate the position of cell
nuclei. A and B, mean of five different experiments is shown. B, BHK cells were incubated with or without fetal
calf serum and then treated with or without U18666A, as indicated. The total amounts of LBPA (arbitrary units
(AU)) and cholesterol (ng) in the fractions were quantified. C, cells were incubated for 1 h at 4 °C with proteo-
liposomes containing LBPA and self-quenching amounts of R18 (t 0). Cells were then incubated at 37 °C for
the indicated time periods, labeled with antibodies against Lamp1, and visualized by double-channel fluores-
cence microscopy (arrowheads point at examples of structures containing both markers). D, total membrane
fractions (microsomes)wereprepared fromBHKcells treated (LBPA) or not (control)with liposomes containing
LBPA. The LBPAcontent of the fractionswas thenquantifiedby ELISAand is expressed in arbitrary fluorescence
units. The mean of four different experiments is shown.
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from endosomes after Alix knockdown, consistent with the
notion that Alix and LBPAmay be involved in endosomal cho-
lesterol retention.
LBPA Addition Using Liposomes—To further investigate the
putative role of Alix and/or LBPA in cholesterol retention,
we decided to re-complement Alix siRNA-treated cells with
LBPA, using LBPA-containing liposomes. To this end, we
synthesized enantiomerically pure (R,R)-2,2-dioleoyl-LBPA
(19), the major (90%) isoform in BHK cells (5, 24) (supple-
mental Fig. S1B). The synthetic lipid was then used to pre-
pare liposomes with a phospholipid composition (DOPC/
DOPE/LBPA; 60:20:20 mol) similar to that of late
endosomes, where LBPA normally resides (5). Because living
cells do not take up liposomes efficiently, the G-glycoprotein
of vesicular stomatitis virus (VSV-G) was incorporated into
the liposomes to increase cell surface binding and targeting
to the endocytic pathway (17). The proteoliposomes bound
anti-LBPA antibodies but not isotypic control antibodies
(supplemental Fig. S4A), indicating that LBPA had retained
its antigenic properties in the liposome bilayer and was thus
presumably present in the same biophysical state as in native
membranes. The G-protein was predominantly incorpo-
rated in its correct orientation, because liposomes could be
immuno-purified with antibodies against an exoplasmic, but
not a cytoplasmic, G-protein epitope (supplemental Fig.
S4B). Finally, these LBPA- and G-containing proteolipo-
FIGURE 3. Recomplementation with 3,3-LBPA. A and B, BHK cells treated with Alix siRNAs were incubated as in Fig. 2C with proteoliposomes containing
2,2-dioleoyl-LBPA (A) or 3,3-dioleoyl-LBPA (B). Then cellswere incubatedwithHRP to label the late endosomecontent andprocessed for electronmicroscopy,
as in Fig. 1,D–E. Bar, 1m. C andD, cells were treatedwith Alix siRNA ormock-treated and thenwith liposomes containing 2,2-dioleoyl-LBPA (siRNA LBPA),
as in B, and processed for fluorescencemicroscopy after stainingwith anti-LBPA antibodies and filipin to reveal cholesterol (C). Filipin stainingwas significantly
reduced after Alix knockdown (middle panels), when comparedwith themock-treated controls (upper panels), and could be restored after recomplementation
with 2,2-dioleoyl-LBPA (lower panels). Cells with a reduced or a normal filipin staining patternwere then counted and are expressed (D) as a percentage of the
total number of cells in each experiment (200 cells from three independent experiments).
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somes were highly fusogenic at low pH but not at neutral pH
(supplemental Fig. S4C), much like VSV itself.
We then testedwhether the liposomes containing exogenous
LBPA were properly targeted to endosomes. Liposomes were
labeled with self-quenching amounts of the fluorescent dye
R18, to monitor fusion, and adsorbed onto control BHK cells
for 1 h at 4 °C. Cells were then incubated for 45min at 37 °C and
analyzed by immunofluorescence.No fluorescence signal could
be detected after liposomebinding to the cell surface on ice (Fig.
2C). Similarly, no signal was detected when cells were allowed
to internalize liposomes for less than 30–45 min at 37 °C (Fig.
2C and not shown), demonstrating
that dye exchange did not occur to
any significant extent under our
conditions. At later time points, R18
fluorescent punctae, revealing lipo-
some fusion, appeared intracellu-
larly. These showed a typical late
endosome-like pattern and colocal-
ized with both Lamp1 (Fig. 2C), a
major glycoprotein of late endo-
somes and lysosomes (39), and with
LBPA itself (supplemental Fig.
S4D). The G-protein showed a sim-
ilar distribution and colocalized
with the late endocytic marker
CD63-GFP (24) (supplemental Fig.
S4E). Using the liposomes, LBPA
delivery was successful, because
LBPA labeling was more intense
and colocalized with Lamp1 (not
show) in typical late endosome-like
structures (supplemental Fig. S4D)
and because the total LBPA con-
tent of liposome-treated cells
increased 2-fold (Fig. 2D), from
1% in control cells (5) to 2% of
total phospholipids. This increase
agrees well with our estimate of
the amount of liposomes taken up
by cells after G-protein quantifica-
tion (not shown).
LBPA Recomplementation after
Alix Depletion—Alix knockdown
causes a concomitant reduction in
both LBPA levels (Fig. 1, A–C) and
lumenal membranes of late endo-
somes (Fig. 1E). We thus used
liposomes to recomplement Alix
siRNA-treated cells with exoge-
nous LBPA. As in Fig. 1, D and E,
late endosomes were labeled with
endocytosed HRP pulsed for 15
min and chased for 30 min at
37 °C. After processing cells for
HRP cytochemistry and electron
microscopy, micrographs were
taken at random and analyzed in a
blind fashion. Strikingly, HRP-labeled structures of cells re-
complemented with 2,2-dioleoyl-LBPA, the main LBPA iso-
form in BHK cells, exhibited the characteristic multivesicu-
lar appearance of late endosomes in BHK cells (Fig. 3A),
which could not be distinguished from the appearance of late
endosomes in controls (see Fig. 1D). These effects were spe-
cific, because recomplementation with the 3,3-dioleoyl-
LBPA isoform did not restore lumenal membranes in late
endosomes (Fig. 3B), which then resembled the empty endo-
somes observed in Alix knockdown cells (Fig. 1E). The
appearance of late endosomes in 3,3-LBPA-treated cells is
FIGURE 4. Model. A, under control conditions, LDL-derived cholesterol esters are de-esterified within the
lumenof late (multivesicular) endosomes. This releases free cholesterol that, due to its lowpartition coefficient,
is likely to become efficiently incorporated into the closest membranes. These are likely to be predominantly
intralumenal membranes, because these are abundant within multivesicular endosomes. Consistently, cho-
lesterol was found to be abundantwithin intralumenalmembranes (3, 4). Cholesterolmust be redistributed to
the endosome-limiting membrane so that it becomes available for export to other cellular destinations, and
this redistribution is likely to involve the back-fusion of intralumenal vesicles (16, 17). B,Alix knockdown causes
a concomitant reduction in the late endosomal phospholipid LBPA (13). In good agreement with the fact that
LBPA is abundant in intralumenal vesicles (5), the late endosomes of Alix knockdown cells are depleted of
intralumenal vesicles. Cholesterol clearance seems to be accelerated, presumably because the cholesterol
buffering capacity of endosomal membranes is decreased when LBPA and lumenal vesicles are reduced. This
notion is further supported by observations that the addition of exogenous LBPA restores both cholesterol
levels and intralumenal membranes within late endosomes. C, LBPA and other lipids accumulate in NPC cells,
concomitantly with an increase in the size of the late endosomal compartment (51), presumably as a compen-
satory mechanism to accommodate excess cholesterol. Obviously, this mechanism does not suffice to over-
come the lipidosis, and eventually cholesterol accumulates beyond the capacity of endosomal membranes,
leading to a traffic jam that collapses the endosomal system (40, 41). Consistently, we find that the addition of
exogenous LBPA toNPC cells reduces thepathological accumulationof cholesterol, presumably because LBPA
became limiting in NPC cells because of cholesterol overload.
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unlikely to result from some undesired effect of this isoform,
because cells containing late endosomes with a normal wild
type morphology were occasionally seen in the same prepa-
rations (Fig. 3B, inset), presumably corresponding to
untransfected cells. These observations fit nicely with our
previous data that 2,2-dioleoyl-LBPA, but not the 3,3-iso-
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form, can interact with Alix and exhibit the inherent capac-
ity to form multivesicular liposomes in vitro (13).
Because addition of exogenous 2,2-dioleoyl-LBPA could
restore lumenal membranes in late endosomes of cells treated
with Alix siRNAs, we wondered whether the same treatment
might overcome the cholesterol deficiency observed after Alix
knockdown (Fig. 1,A andB).We could not quantify cholesterol
directly in these siRNA- and liposome-treated cells, because
amounts were limiting. However, an analysis by light micros-
copy showed that addition of exogenous 2,2-dioleoyl-LBPA
restored the cholesterol distribution observed after filipin
staining, much like LBPA itself (Fig. 3C; quantification in D).
Cholesterol staining showed the characteristic pattern
observed in controls, presumably corresponding to the plasma
membrane, endosomes, and trans-Golgi network (8, 29). These
depletion-recomplementation experiments indicate that LBPA
plays a direct role in themaintenance of endosomal cholesterol
levels. Under physiological conditions, cholesterol accumulates
in intralumenal membranes (3, 4), suggesting that free choles-
terol, e.g. released after LDL endocytosis and de-esterification,
is captured by LBPA-rich internal membranes, presumably
because these are more abundant than the limiting membrane
(5). In siRNA-treated cells, when LBPA levels are decreased and
lumenal membranes reduced (Fig. 1), cholesterol may not be
efficiently retained in endosomes, leading to increased leakage
(see model Fig. 4). By restoring lumenal membranes (Fig. 3B),
the addition of exogenous LBPA presumably also restores the
endosomal capacity to store cholesterol (Fig. 3, C and D). We
thus conclude that LBPA itself plays a direct role in the main-
tenance of endosomal cholesterol, perhaps because LBPA-rich
membranes help buffer membrane cholesterol (Fig. 4).
Niemann-Pick Type C Cholesterol Storage Disorder—The
existence of a link between cholesterol storage and LBPA mem-
branes is further supportedbyobservations thatLBPAandcholes-
terol shift in parallel under diverse cellular conditions. Cholesterol
decreases when LBPA decreases after Alix knockdown and is
restored upon LBPA re-loading. Consistently, both are also
decreaseduponsterol carrierprotein-2expression (6).Conversely,
LBPAaccumulateswhencholesterol accumulates in vitro (Fig. 2B)
and inNPC cells in vivo (12). Itmay be that cholesterol accumula-
tion and LBPA are not linked functionally in NPC cells. There is,
however, a distinct possibility that LBPAandother lipids accumu-
late in diseased cells as a compensatory mechanism to accommo-
date excess cholesterol. Obviously, if this is the case, this mecha-
nism does not suffice to overcome the lipidosis; Alix is unlikely to
be limiting, because its expression does not change in NPC or
U18666A-treatedcells (not shown).Onemight thus speculate that
LBPA increases in diseased cells to compensate for cholesterol
accumulation, until LBPA production and the endosomal system
collapseundercholesteroloverload (40, 41). LBPAitselfmayeven-
tually become limiting inNPC cells (seemodel Fig. 4). To test this
hypothesis, we treated well established 93.41 human NPC skin
fibroblasts (42, 43), with LBPA-containing liposomes.
After treatment with proteoliposomes containing LBPA for
8 h at 37 °C, as above (Fig. 2C and Fig. 3C), LBPAwas increased
1.6-fold (Fig. 5C), a range similar to that observed in BHK
cells (Fig. 2D). Strikingly, cholesterol accumulation was signif-
icantly reduced in most liposome-treated NPC cells (Fig. 5A),
which then showed an intracellular pattern reminiscent of
healthy cells (see Fig. 1A and Fig. 3C), including fibroblasts (7).
To quantify these effects, NPC cells were divided into the fol-
lowing three categories, because of their heterogeneous pheno-
type: (i) strong accumulation of cholesterol, which sometimes
occupied most of the cytoplasm volume; (ii) reduced (interme-
diate); (iii) low accumulation (Fig. 5, B and D). (Some differ-
ences in the percentages of cells in each category in Fig. 5,B and
D, reflect variations in separate series of experiments presum-
ably because of culture conditions.) LBPA-containing lipo-
somes reduced the number of cells with a strong phenotype
2–3-fold, with a concomitant increase in cells with interme-
diate and mild phenotypes (Fig. 5, B andD). These effects were
specific, because liposomes lacking LBPAwere essentiallywith-
out effects, whereas liposomes that contained 20mol % choles-
terol (DOPC/DOPE/cholesterol, 60:20:20), instead of 20 mol %
LBPA, further increased cholesterol levels (Fig. 5B).
LBPA Isoforms and Analogues—The observed effects were
also specific for the 2,2-dioleoyl-LBPA isoform, because cho-
lesterol accumulation was not significantly affected by lipo-
somes containing 3,3-dioleoyl-LBPA or a triple acylated ver-
sion of the lipid (semi-LBPA) (Fig. 2A), which was reported to
be present in vaccinia virus and perhaps in the Golgi apparatus
(44) (Fig. 5B). Hence, esterification of the acyl chains to the 2-
and 2-positions of the glycerol backbone is essential for LBPA
function in cholesterol clearance. It is attractive to believe that
LBPA functions in cholesterol clearance and endosomal mem-
brane dynamics are linked because 2,2-LBPA but not 3–3
LBPA (i) interacts with Alix, (ii) supports the invagination of
artificial membranes in vitro (13), and (iii) restores lumenal
membranes in Alix knockdown cells (Fig. 3A).
Because acyl chain addition to the 2- and 2-positions is
essential for LBPA functions, we then investigated whether the
2- and 2-linking groups were also important. Liposomes con-
taining either the enantiomeric R,R or S,S form of the bis-ether
analogue of (R,R)-2,2-dioleoyl-LBPA (20) (supplemental Fig.
FIGURE 5. Effects of LBPA-liposomes on NPC cells. A, NPC cells were treated or not with liposomes containing LBPA, as indicated, and cholesterol patterns
were visualized after filipin staining by fluorescence microscopy. Exposure times were selected to reveal the intracellular distribution of cholesterol in lipo-
some-treated cells.B,NPCcellswere treatedwith the following liposomepreparations andanalyzedas inA: control liposomeswithout LBPA (ctrl lip); liposomes
containing 3,3-dioleoyl-LBPA (3,3-LBPA); liposomes containing 2,2-dioleoyl LBPA (2,2-LBPA); liposomes containing semi-LBPA; liposomes containing cho-
lesterol. For quantification, cells were divided into three categories according to the intensity of the cholesterol-staining pattern, as indicated. The number of
cells in each category is counted and expressed as a percentage of the total cells in the corresponding experiment. C, total membrane fractions (microsomes)
were prepared fromNPC cells treated (LBPA) or not (control) with liposomes containing LBPA. The LBPA content of the fractions was then quantified by ELISA
and is expressed in arbitrary fluorescence units. Compare with Fig. 2D for values in BHK cells. D, NPC cells were treated with the following liposome prepara-
tions, analyzed as in A, and quantified as in B: control liposomes without LBPA (ctrl lip); liposomes containing 2,2-dioleoyl LBPA (2,2-LBPA); liposomes
containing (R,R)- or (S,S)-bis-ether LBPA analogues (bis(3-hydroxy-2(R)-O-oleyl-sn-glycero-1-)phosphate and bis(3-hydroxy-2(S)-O-oleyl-sn-glycero-1-)phos-
phate, respectively. Differences in the percentages of cells in each category in B andD presumably reflect variations because of culture conditions in separate
series of experiments. B–D,mean of at least three independent experiments is shown.
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S1B) did not show any significant effect when compared with
the natural bis-ester lipid (Fig. 5D). This further establishes the
specificity of 2,2-LBPA action in cholesterol clearance and
demonstrates that acylation to the glycerol backbone via a car-
bonyl group is required for function. Altogether, these data
show that cholesterol clearance from NPC endosomes is facil-
itated by the addition of exogenous LBPA, indicating that LBPA
itself becomes limiting in the disease, presumably because cho-
lesterol has accumulated beyond the capacity of endosomal
membranes. Similarly, M87 mutant Chinese hamster ovary
cells harbor a mutation in a gene distinct from NPC1 or NPC2
but show NPC-like cholesterol accumulation in late endocytic
compartments, perhaps because excessive internalization of
LDL cholesterol exceeds the capacity of NPC1-containing late
endosomes and leads to cholesterol accumulation (31). Then
this pathological accumulation causes a complete traffic jam
that collapses the endosomal system (40, 41) and eventually
interferes with cholesterol-dependent functions of endosomes
(28), including early-to-late endosome transport (45) and late
endosome motility (46, 47). It is attractive to speculate that
LBPAmay play a similar role in other lipidoses that are accom-
panied by cholesterol accumulation in endosomes and lyso-
somes (48, 49). In conclusion, our observations indicate that the
precise modulation of a specific, natural lipid species in a tar-
geted organelle can lead to the partial reversion of a disease
phenotype. The identification of LBPAmetabolic enzymesmay
thus provide new biomedical strategies to overcome some of
the problems anddefects associatedwith these storage diseases.
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LEGENDS OF SUPPLEMENTARY FIGURES 
 
Fig S1. Alix RNAi target sequence and LBPA isoforms. (A) Alix sequence in BHK cells was 
determined by RT-PCR and the 21-mer of the sequence used as target for siRNAs (boxed in red) was 
determined and found to be identical to the human sequence. (B) The chemical composition of the 
different LBPA isoforms and analogues used in the paper is shown (R is C18:1 in the major 2,2’-
LBPA isoform of BHK cells). 
 
Fig S2. Alix knockdown does not affect the expression of genes involved in cholesterol synthesis and 
accumulation. Cells were treated with Alix siRNAs or mock-treated, and the expression of the 
indicated genes was measured by RT-PCR. DHC: dehydrocholesterol reductase; SREB: sterol 
regulatory element binding transcription factor 2: LDLR: low density lipoprotein (LDL) receptor; 
SDH: succinate dehydrogenase subunit A. The data represent the mean of three independent 
experiments; standard errors of the mean are shown. 
 
Fig S3. Cholesterol accumulation after U18666A treatment. Mock- or Alix siRNA-treated BHK cells 
were incubated with U18666A for the indicated time. Cells were labeled with filipin and analyzed by 
fluorescence microscopy. Before the experiment (t=0h), cells were also labeled with anti-LBPA 
antibodies, to illustrate the decrease in both LBPA and cholesterol after Alix knockdown (lower 
panels). Stars indicate the position of cell nuclei, and arrows point at examples of endosomes 
containing cholesterol. 
 
Fig S4. LBPA-containing liposomes. (A) Antibodies against LBPA (anti-LBPA) or an isotypic control 
antibody (isotypic ctrl) were incubated with LBPA-containing liposomes. Liposome-bound (bound) 
and free (free) antibody were separated by floatation in a sucrose gradient. Antibody binding was 
analyzed by SDS gel electrophoresis under non-reducing conditions, followed by western blotting 
with anti-mouse antibodies (mouse IgG indicated by an arrow). (B) Liposomes containing VSV-G 
were immuno-purified with antibodies against a VSV-G exoplasmic epitope (17.2.21.4 ; exo) or 
cytoplasmic epitope (P5D4, cyto), and analyzed by SDS gel electrophoresis under non-reducing 
conditions followed by western blotting with a polyclonal anti VSV-G antibody. Arrows point at the 
VSV-G doublet. (C) The fusion capacity of liposomes containing the G-protein and LBPA (acceptor 
liposomes) was measured at pH 7.4 or 5.6, by quantifying the dequenching of R18 fluorescence, using 
R18-contanining liposomes as donor. (D) Cells were incubated for 1h at 4°C with proteoliposomes 
containing LBPA and the G-protein, as well as self-quenching amounts of R18 (as in Fig 2B), and 
then for 45min at 37°C to allow endocytosis of the bound liposomes to occur. Cells were then labeled 
with antibodies against LBPA, and visualized by double-channel fluorescence microscopy. All R18-
contaning structures also contain LBPA, while LBPA shows a broader distribution presumably 
because some endosomes contain endogenous LBPA but not R18. (E) The experiment was as in (D), 
except that cells transfected with CD63-GFP were used and that R18 was omitted. Cells were then 
labeled with antibodies against VSV-G, and visualized by double-channel fluorescence microscopy. In 
(D-E) arrow point at examples of structures containing both markers. 
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